Economic evaluations in evidence based healthcare

Evidence-Based Mental Health

Volumn 12, Issue 2, 2009, Pages 36-39

  Barrett, Barbara ^a   Byford, Sarah ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST; COST BENEFIT ANALYSIS; ECONOMICS; EVIDENCE BASED PRACTICE; MENTAL DISEASE; MENTAL HEALTH SERVICE;

COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; EVIDENCE-BASED PRACTICE; MENTAL DISORDERS; MENTAL HEALTH SERVICES;

EID: 65249145157     PISSN: 13620347     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebmh.12.2.36     Document Type: Article

References (20)

1. Sackett DL, Rosenberg WMC, Gray JAM, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312:71-2.
2. Hotopf M. The pragmatic randomised controlled trial. Adv Psychiatr Treat 2002; 8:326-33.
3. McCrone P, Dhanasiri S, Patel A, et al. Paying the price: The cost of mental health care in England to 2026. London: King's Fund, 2008.
4. Rutherford D. Houtledge dictionary of economics. London: Routledge, 1995.
5. Bannock G, Baxter RE, Davis E. The Penguin dictionary of economics. London: Penguin Books, 1987.
6. Braae R, McNee W, Moore D. Managing pharmaceutical expenditure while increasing access: The Pharmaceutical Management Agency (PHARMAC) experience. Pharmacoeconomics 1999; 16:649-60.
7. Duckett SJ. Drug Policy Down Under: Australia's Pharmaceutical Benefits Scheme. Health Care Financ Rev 2008; 25:55-67.
8. McMahon M, Morgan S, Mitton C. The Common Drug Review: A NICE start for Canada? Health Policy 2006:77:339-51.
9. National Institute for Health and Clinical Excellence. A guide to NICE. London: NICE, 2005.
10. Drummond M, Sculpher M, Torrance GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005.
11. Johnston K, Buxton MJ, Jones DR, et al. Assessing the costs of healthcare technologies in clinical trial. Health Technol Assess 1999; 3:1-86.
12. Brazier J, Ratcliffe J, Salomen JA, et al. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press, 2007.
13. Kind P. The EuroQol instrument: an index of health related quality of life. In Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven, 1996:191-201.
14. Brazier J, Roberts J, Deverill M. Th estimation of a preference-based single index measure for health from the SF-36. J Health Econ 2002; 21:271-92.
15. National Institute for Health and Clinical Excellence. Methods for technology appraisal. London: NICE, 2008.
16. Chisholm D, Healey A, Knapp M. QALYs and mental health. Soc Psychiatry Psychiatr Epidemiol 1997; 32:68-75.
17. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005; 187: 106-8.
18. Byford S, McCrone P, Barrett B. Developments in the quantity and quality of economic evaluations in mental health. Curr Opin Psychiatry 2003; 16:703-7.
19. McCrone P, Knapp M, Proudfoot J, et al. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 2004; 185:55-62.
20. Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007; 191:14-22.